Contributors

Molly Billstein Leber, PharmD, BCPS, FASHP, is manager, Medication Policy and Formulary Management, Yale New Haven System in New Haven, Connecticut. She received her PharmD degree from the University of Montana and completed a PGY1 Residency at Yale New Haven Hospital. Leber’s career focuses on formulary standardization, drug use policy, pharmacy informatics, and promoting safe and efficient use of medications.
John Bujnoski is Managing Director of Pangea Advisory and Consulting, LLC, a strategic marketing consulting firm focused on the specialty biopharmaceutical and biosimilar market segments. John has extensive global biopharmaceutical industry expertise including extensive knowledge and understanding of the global market environment including pricing, market access, and reimbursement systems.
Kashyap Patel, MD, is the managing partner at Carolina Blood and Cancer Care and has been with them since its inception in 2004. Dr Patel received his medical degree from Thomas Jefferson University Hospital, has authored several research articles regarding melanoma, and is board certified in hematology, oncology, and internal medicine.
Angus Worthing, MD, FACR, FACP, is a practicing rheumatologist at Arthritis & Rheumatism Associates in Washington, DC and chair of the American College of Rheumatology's Government Affairs Committee. He is a director of the Medical Society of the District of Columbia, chair of the Public Policy Education Committee of the Rheumatism Society of the District of Columbia, and a frequent speaker on policy issues related to rheumatology care.
George C. Yu, JD, is a partner in the Intellectual Property group of Schiff Hardin LLP. He is an experienced patent attorney who focuses his practice focuses on patent infringement litigation and counseling and has worked in private practice and in-house positions. George has litigated patents relating to recombinant proteins, monoclonal antibodies, microarray technology, and small molecule therapeutics. George has advised companies developing novel biologics as well as biosimilars on patent strategy.
  Christopher Bruno, JD, is an associate in the Intellectual Property group at Schiff Hardin LLP, and a former law clerk of the United States Court of Appeals for the Federal Circuit and of the United States District Court for the Central District of California. With a focus on pharmaceutical product patent litigation, he has litigated Hatch-Waxman cases from pre-complaint investigation through appeal in district courts, the Federal Circuit, the Supreme Court, and the International Trade Commission. Chris was one of the first attorneys with experience litigating the meaning of provisions of the Biologics Price Competition and Innovation Act of 2009, and continues to play a role in decoding the relatively nascent territory of biosimilar litigation.
Amanda Forys, MSPH, is a Director at Xcenda, a part of AmerisourceBergen, on the Reimbursement Strategy Insights consulting team. Her experience includes reimbursement policy analytics, with emphases on Medicare and commercial coverage and payment policy. Her work has covered a wide range of topics, including economic and policy modeling and analysis around biosimilars, innovative payment models, chronic disease management, federal budgetary impact models, and Medicare payment systems. 
Sonia T. Oskouei, PharmD, is the Director of Pharmacy Program Development for Biosimilars at Premier Inc. Within the provider-led organization, she has the unique role of leading the national biosimilar strategy on behalf of nearly 3800 hospitals and health systems. Through the development of educational resources and tools, she supports health system stakeholders evaluate and manage biosimilars, and works with biosimilar manufacturers on market considerations including financial, clinical, and operational decisions. She previously oversaw pharmacy purchasing and procurement for Novant Health. 
Stacie Phan, MBA, MS, is president of the Biosimilars Forum. Ms. Phan has more than 20 years of experience in pharmaceutical research, government affairs, public policy analysis, and business operations. Currently she is Director of State Government Affairs and Public Policy, serving as Boehringer Ingelheim’s state government relations lead and key strategist for researching and developing company positions on public policy issues in the United States. Previously, Ms. Phan worked at Bayer HealthCare in public policy including reimbursement policy, oncology, and hemophilia.

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2017 Intellisphere, LLC. All Rights Reserved.